Diurnal Group plc (DNL:LSE) Annual Reports & Investor Relations Material

Overview

Diurnal Group plc is a specialty pharmaceutical company that develops hormone therapeutics for the treatment of chronic endocrine conditions. Based in Cardiff, UK, the company's products aim to address conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal Group's flagship products include Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe, and Chronocort, which has completed Phase III clinical trials for targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline includes Native Oral Testosterone, siRNA oligonucleotide therapy, and T3 modified hormone therapy.

Frequently Asked Questions

What is Diurnal Group plc's ticker?

Diurnal Group plc's ticker is DNL

What exchange is Diurnal Group plc traded on?

The company's shares trade on the LSE stock exchange

Where are Diurnal Group plc's headquarters?

They are based in Cardiff, Wales

How many employees does Diurnal Group plc have?

There are 11-50 employees working at Diurnal Group plc

What is Diurnal Group plc's website?

It is https://www.diurnal.com/

What type of sector is Diurnal Group plc?

Diurnal Group plc is in the Healthcare sector

What type of industry is Diurnal Group plc?

Diurnal Group plc is in the Drug Manufacturers - Other industry

Who are Diurnal Group plc's peers and competitors?

The following five companies are Diurnal Group plc's industry peers:

- PetIQ

- Geron

- AbbVie

- Cann Global Limited

- The Supreme Cannabis Company, Inc.